Chinese researchers have pioneered a groundbreaking biomimetic platform that significantly enhances the effectiveness of CAR-T therapy for leukemia patients. This innovative approach, described as ‘molecular double-sided tape,’ addresses the critical challenge of cancer relapse that affects over 50% of patients following conventional treatment.
The technology, detailed in the prestigious journal Cell, centers on the discovery that CD71—a protein responsible for iron transport—shows consistently high expression across various leukemia types and disease stages. Leveraging this biological feature, scientists from the Chinese Academy of Sciences’ Institute of Process Engineering developed the Ferritin Aggregation Cell Engager (FACE) platform through precisely controlled solvent-induced self-assembly.
Unlike traditional methods that require complex genetic reengineering of CAR-T cells, the FACE platform integrates seamlessly with existing treatment protocols. During the 30-minute preparation phase, FACE anchors to CAR-T cells via CD71 receptors. Upon administration, it simultaneously attaches to leukemia cells, creating a reinforced connection that dramatically improves cancer cell recognition and elimination.
In preclinical trials using patient-derived leukemia models, the technology demonstrated remarkable efficacy. The FACE-enhanced therapy achieved equivalent therapeutic outcomes using only 20% of the conventional CAR-T cell dosage while substantially reducing adverse effects. Most notably, the platform remained effective even when cancer antigens dropped below 10% of normal levels—a condition that typically renders leukemia cells undetectable to standard CAR-T cells.
The researchers further advanced the technology by developing a drug-loaded variant that delivers chemotherapy directly to cancer cells. This combined approach proves particularly effective against antigen-negative escapees that commonly evade conventional treatments.
Professor Wei Wei, corresponding author of the study, emphasized the clinical advantages: ‘Our FACE platform utilizes endogenous proteins and FDA-approved polymer derivatives, manufactured through a simple, scalable process. It integrates seamlessly into existing CAR-T workflows without additional genetic engineering.’
The technology has been validated across multiple leukemia subtypes and treatment-resistant scenarios using both mouse models and human patient samples. The research team has additionally established an efficacy database and AI-powered predictive framework to support clinical translation and treatment optimization.
Peer reviewers at Cell have endorsed the approach as ‘a promising translational strategy’ with potential applications across various blood cancers, highlighting its adaptability to diverse clinical settings and capacity to address leukemia antigen variability.
